drugset / Trial / NCT04816123

The Mass Balance and Biotransformation of [14C]Donafenib in Healthy Adult Man

NCT04816123

Phase 1 Completed 6 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NaSingle-groupOpen-labelOther

Summary

This study was designed to evaluate the mass balance and biotransformation after single-dose of \[14C\]Donafenib orally in Chinese healthy adult male volunteers, revealing the overall pharmacokinetic characteristics of Donafenib in humans, and providing a reference for the rational administration.

Timeline

Start
2018-10-09
Primary completion
2018-12-18
Completion
2018-12-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Donafenib Small molecule 300 mg Oral

Indications

No indication recorded.